SRDX : Summary for Surmodics, Inc. - Yahoo Finance

U.S. Markets open in 2 hrs 58 mins

Surmodics, Inc. (SRDX)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
23.75-0.20 (-0.84%)
At close: 4:00 PM EST
People also watch:
VASCTECHSPNCICUIVIVO
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close23.95
Open0.00
Bid0.00 x
Ask0.00 x
Day's Range23.75 - 24.15
52 Week Range17.45 - 30.75
Volume29,770
Avg. Volume56,063
Market Cap309.84M
Beta0.65
PE Ratio (TTM)31.25
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • SurModics, Inc. :SRDX-US: Earnings Analysis: Q4, 2016 By the Numbers : November 23, 2016
    Capital Cube12 days ago

    SurModics, Inc. :SRDX-US: Earnings Analysis: Q4, 2016 By the Numbers : November 23, 2016

    Categories: Yahoo Finance Get free summary analysis SurModics, Inc. reports financial results for the quarter ended September 30, 2016. We analyze the earnings along side the following peers of SurModics, Inc. – Nektar Therapeutics, Thermo Fisher Scientific Inc., Heron Therapeutics Inc, Abbott Laboratories, pSivida Corp., Johnson & Johnson, PerkinElmer, Inc., Alkermes Plc and Agilent Technologies, Inc. (NKTR-US, TMO-US, ... Read more (Read more...)

  • Business Wire13 days ago

    Surmodics to Attend Piper Jaffray Healthcare Conference

    Surmodics, Inc. , a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that Gary Maharaj, president and chief executive officer, and Andy LaFrence, vice president of finance and information systems and chief financial officer, will attend the 28th Annual Piper Jaffray Healthcare Conference in New York City on Tuesday, November 29, 2016....

  • SurModics (SRDX) Beats Q4 Earnings & Revenues Estimates
    Zacks18 days ago

    SurModics (SRDX) Beats Q4 Earnings & Revenues Estimates

    SurModics' (SRDX) fourth-quarter of fiscal 2016 adjusted earnings of 26 cents per share beat the Zacks Consensus Estimate of 9 cents.